# A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

> **NCT04480710** · PHASE2 · COMPLETED · sponsor: **Hepion Pharmaceuticals, Inc.** · enrollment: 47 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis
- Fibrosis, Liver
- NAFLD - Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** CRV431 75mg
- **DRUG:** Placebo (1 softgel)
- **DRUG:** CRV431 225mg
- **DRUG:** Placebo (3 softgels)

## Key facts

- **NCT ID:** NCT04480710
- **Lead sponsor:** Hepion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-10-30
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480710, "A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04480710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*